Mondelēz Global LLC Conducts Nationwide Voluntary – Recall of Oreo Fudge Cremes Product Sold in the U.S. Recall Due to Milk Allergen Not Listed in Ingredient Line

Mondelez Global LLC of East Hanover, NJ, announced today a nationwide voluntary recall in the United States, including the U.S. Territories of Puerto Rico, St. Croix and St. Thomas, of certain Oreo Fudge Cremes product, Original and Mint varieties, due to milk allergen not being declared in the ingredient list. Mondelez Global LLC is taking this action out of an abundance of caution.

Mondelēz Global LLC Conducts Nationwide Voluntary – Recall of Oreo Fudge Cremes Product Sold in the U.S. Recall Due to Milk Allergen Not Listed in Ingredient Line

Mondelez Global LLC of East Hanover, NJ, announced today a nationwide voluntary recall in the United States, including the U.S. Territories of Puerto Rico, St. Croix and St. Thomas, of certain Oreo Fudge Cremes product, Original and Mint varieties, due to milk allergen not being declared in the ingredient list. Mondelez Global LLC is taking this action out of an abundance of caution.

FDA approves new device for prevention of recurrent strokes in certain patients

The U.S. Food and Drug Administration today approved the Amplatzer PFO Occluder device. The PFO Occluder reduces the risk of a stroke in patients who previously had a stroke believed to be caused by a blood clot that passed through a small hole in the heart, called a patent foramen ovale (PFO), and then traveled to the brain.

Back to Nature Issues a Product Recall and Allergy Alert for Chocolate Chunk Cookies, Mini Chocolate Chunk Cookies and Chocolate Granola Due to Undeclared Milk

Back to Nature Foods, LLC is voluntarily recalling four (4) products because those products contain chocolate purchased from a third party supplier which was found to contain undeclared Milk that is not listed as an ingredient on the label.
Read The Complete Story!

FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma

The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment.